• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Achieve Life Sciences Inc.

    5/17/24 2:56:31 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ACHV alert in real time by email
    SC 13G 1 propelbiomanagement_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. ___)*

     

    Achieve Life Sciences, Inc.

     

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    004468500

     

    (CUSIP Number)

     

    3/4/2024

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)
    ☒Rule 13d-1(c)
    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    1.

    Names of Reporting Persons.

     

    Propel Bio Management LLC

    2.

    Check the Appropriate Box if a Member of a Group

         

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    2,235,247

    6.

    Shared Voting Power

     

    98,929

    7.

    Sole Dispositive Power

     

    2,235,247

    8.

    Shared Dispositive Power

     

    98,929

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,334,176 (1)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

        ☐  
    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.81% (1)(2)

    12.

    Type of Reporting Person

     

    IA

           
    (1)The beneficial ownership of the securities reported herein is described in item 4 of this Schedule 13G.
    (2)Calculations are based on 34,251,911 common shares outstanding as of March 28, 2024, as disclosed by the Issuer on its Form 10-K filed with the Securities and Exchange Commission on March 28, 2024.

     

    1

     

     

    1.

    Names of Reporting Persons.

     

    Leen Kawas

    2.

    Check the Appropriate Box if a Member of a Group

         

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    2,235,247

    6.

    Shared Voting Power

     

    98,929

    7.

    Sole Dispositive Power

     

    2,235,247

    8.

    Shared Dispositive Power

     

    98,929

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,334,176 (1)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

        ☐  
    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.81% (1)(2)

    12.

    Type of Reporting Person

     

    IN

           
    (1)

    The beneficial ownership of the securities reported herein is described in item 4 of this Schedule 13G.

    (2)

    Calculations are based on 34,251,911 common shares outstanding as of March 28, 2024, as disclosed by the Issuer on its Form 10-K filed with the Securities and Exchange Commission on March 28, 2024.

     

    2

     

     

    1.

    Names of Reporting Persons.

     

    Richard Kayne

    2.

    Check the Appropriate Box if a Member of a Group

         

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    United States

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    2,235,247

    6.

    Shared Voting Power

     

    98,929

    7.

    Sole Dispositive Power

     

    2,235,247

    8.

    Shared Dispositive Power

     

    98,929

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,334,176 (1)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

        ☐  
    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.81% (1)(2)

    12.

    Type of Reporting Person

     

    IN

           
    (1)

    The beneficial ownership of the securities reported herein is described in item 4 of this Schedule 13G.

    (2)

    Calculations are based on 34,251,911 common shares outstanding as of March 28, 2024, as disclosed by the Issuer on its Form 10-K filed with the Securities and Exchange Commission on March 28, 2024.

     

    3

     

     

    1.

    Names of Reporting Persons.

     

    Propel Bio Partners LLC

    2.

    Check the Appropriate Box if a Member of a Group

         

    (a) ☐

    (b) ☐

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

    5.

    Sole Voting Power

     

    2,235,247

    6.

    Shared Voting Power

     

    98,929

    7.

    Sole Dispositive Power

     

    2,235,247

    8.

    Shared Dispositive Power

     

    98,929

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,334,176 (1)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

        ☐  
    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.81% (1)(2)

    12.

    Type of Reporting Person

     

    OO

           
    (1)

    The beneficial ownership of the securities reported herein is described in item 4 of this Schedule 13G.

    (2)

    Calculations are based on 34,251,911 common shares outstanding as of March 28, 2024, as disclosed by the Issuer on its Form 10-K filed with the Securities and Exchange Commission on March 28, 2024.

     

    4

     

     

    ITEM 1.

     

      (a) Name of Issuer: Achieve Life Sciences, Inc.

     

      (b) Address of Issuer’s Principal Executive Offices:

     

    22722 29th Drive SE, Suite 100

    Bothell, WA 98021

     

    ITEM 2.

     

    Propel Bio Management, LLC

     

      (a) Name of Person Filing: Propel Bio Management, LLC

     

      (b) Address of Principal Business Office, or if None, Residence:

     

    11620 Wilshire Blvd.

    Suite 350

    Los Angeles, CA 90025

     

      (c) Citizenship: Delaware

     

      (d) Title of Class of Securities: Common Stock, $0.0001 par value per share

     

    (e)

    CUSIP Number: 004468500

     

    Leen Kawas

     

      (a) Name of Person Filing: Leen Kawas

     

      (b) Address of Principal Business Office, or if None, Residence:

     

    11620 Wilshire Blvd.

    Suite 350

    Los Angeles, CA 90025

     

      (c) Citizenship: United States

     

      (d) Title of Class of Securities: Common Stock, $0.0001 par value per share

     

      (e) CUSIP Number: 004468500

     

    Richard Kayne

     

    (a) Name of Person Filing: Richard Kayne

     

      (b) Address of Principal Business Office, or if None, Residence:

     

    11620 Wilshire Blvd.

    Suite 350

    Los Angeles, CA 90025

     

    5

     

     

      (c) Citizenship: United States

     

      (d) Title of Class of Securities: Common Stock, $0.001 par value per share
         
      (e)

    CUSIP Number: 004468500

     

    Propel Bio Partners LLC

     

      (a) Name of Person Filing: Propel Bio Partners LLC

     

      (b) Address of Principal Business Office, or if None, Residence:

     

    11620 Wilshire Blvd.

    Suite 350

    Los Angeles, CA 90025

     

      (c) Citizenship: California

     

      (d)

    Title of Class of Securities: Common Stock, $0.001 par value per share

     

      (e) CUSIP Number: 004468500

     

    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).

     

    6

     

     

    ITEM 4. OWNERSHIP.

     

    Propel Bio Management, LLC

     

      (a) Amount beneficially owned: 2,334,176 (1)(2)(4)

     

      (b) Percent of class: 6.81% (1)(2)(4)

     

      (c) Number of shares as to which the person has:

     

      (i) Sole power to vote or to direct the vote: 2,235,247

     

      (ii) Shared power to vote or to direct the vote: 98,929

     

      (iii) Sole power to dispose or to direct the disposition of: 2,235,247

     

      (iv) Shared power to dispose or to direct the disposition of: 98,929

     

    Leen Kawas

     

      (a) Amount beneficially owned: 2,334,176 (1)(2)(4)

     

      (b) Percent of class: 6.81% (1)(2)(4)

     

      (c) Number of shares as to which the person has:

     

      (i) Sole power to vote or to direct the vote: 2,235,247

     

      (ii) Shared power to vote or to direct the vote: 98,929

     

      (iii) Sole power to dispose or to direct the disposition of: 2,235,247

     

      (iv) Shared power to dispose or to direct the disposition of: 98,929

     

    Ric Kayne

     

      (a) Amount beneficially owned: 2,334,176 (1)(2)(4)

     

      (b) Percent of class: 6.81% (1)(2)(4)

     

      (c) Number of shares as to which the person has:

     

      (i) Sole power to vote or to direct the vote: 2,235,247

     

      (ii) Shared power to vote or to direct the vote: 98,929

     

      (iii) Sole power to dispose or to direct the disposition of: 2,235,247

     

      (iv) Shared power to dispose or to direct the disposition of: 98,929

     

    7

     

     

    Propel Bio Partners LLC

     

      (a) Amount beneficially owned: 2,334,176 (2)(3)(4)

     

      (b) Percent of class: 6.81% (2)(3)(4)

     

      (c) Number of shares as to which the person has:

     

      (i) Sole power to vote or to direct the vote: 2,235,247

     

      (ii) Shared power to vote or to direct the vote: 98,929

     

      (iii) Sole power to dispose or to direct the disposition of: 2,235,247

     

      (iv) Shared power to dispose or to direct the disposition of: 98,929

     

    FOOTNOTES

     

    (1) 2,334,176 Shares are directly owned by a private investment fund, special purpose vehicle and an investment company registered under the Investment Company Act of 1940, as amended, for which Propel Bio Management LLC (“Propel”) and Ms. Kawas provide discretionary advisory services. Ms. Kawas is the sole owner of Propel, and possesses voting control and/or the power to direct the disposition of the Shares. Accordingly, for purposes of Rule 13d-3, Propel and Ms. Kawas may be deemed to beneficially own the Shares. In accordance with Rule 13d-4, Propel and Ms. Kawas expressly disclaim beneficial ownership of the Shares.
    (2) Calculations are based on 34,251,911 common shares outstanding as of March 28, 2024, as disclosed by the Issuer on its Form 10-K filed with the Securities and Exchange Commission on March 28, 2024.
    (3) Propel Bio Partners LLC (“General Partner”) serves as the general partner to a private investment fund managed by Propel. Ms. Kawas and Mr. Kayne are control persons of the General Partner. For purposes of Rule 13d-3, the General Partner possesses voting control and/or power to direct the disposition of the Shares held by the private fund. In accordance with Rule 13d-4, Ms. Kawas, Mr. Kayne, and the General Partner each expressly disclaim beneficial ownership of the Shares.
    (4) In accordance with Rule 13d-4, Ms. Kawas, Mr. Kayne, and the General Partner each expressly disclaim beneficial ownership of the Shares.

     

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

     

    Reporting persons are holding 6.81% of the shares in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities.

     

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

     

    Not Applicable.

     

    8

     

     

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

     

    Not Applicable.

     

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP.

     

    Not Applicable.

     

    ITEM 10. CERTIFICATION.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

    9

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      May 17, 2024
      Date
       
      /s/ Leen Kawas/Managing Member
      Signature
       
      Leen Kawas/Managing Member
      Name/Title

     

    10

    Get the next $ACHV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACHV

    DatePrice TargetRatingAnalyst
    11/14/2024$12.00Buy
    Rodman & Renshaw
    9/27/2024$20.00Strong Buy
    Raymond James
    5/10/2023$8.00 → $20.00Buy
    Maxim Group
    10/4/2021$25.00Buy
    Alliance Global Partners
    6/23/2021$23.00Outperform
    Oppenheimer
    More analyst ratings

    $ACHV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

      Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for first quarter 2025 and confirmed that it plans to submit the upcoming New Drug Application (NDA) for cytisinicline to the U.S. Food and Drug Administration (FDA) in June 2025. "The Achieve team is fully

      5/13/25 7:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

      SEATTLE and VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that it will report its first quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday May 13, 2025, at 8:30 AM EDT. To access the webcast, please use the following link: 1Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and r

      5/6/25 8:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine

      ORCA-3 Demonstrated a Significant Increase in Quitting and Reduction in Nicotine Cravings for Cytisinicline-Treated Participants Compared to Placebo Cytisinicline New Drug Application (NDA) Submission to FDA Planned for June 2025 SEATTLE and VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that complete trial results from its ORCA-3 were published in the Journal of the American Medical Association (JAMA) Internal Medicine. ORCA-3 was the

      4/21/25 11:19:48 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Oki Mark K bought $28,887 worth of shares (10,000 units at $2.89) (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/19/25 4:38:43 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chieve Executive Officer Stewart Richard Alistair bought $28,598 worth of shares (10,000 units at $2.86), increasing direct ownership by 20% to 60,876 units (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/19/25 4:32:22 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Stewart Richard Alistair bought $45,850 worth of shares (10,000 units at $4.58), increasing direct ownership by 35% to 38,501 units (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/6/24 4:49:23 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    Leadership Updates

    Live Leadership Updates

    See more
    • Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

      SEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Kristen Slaoui, Ph.D., and Nancy Phelan will join its Board of Directors. Achieve also announced that current Board member, Vaughn Himes, Ph.D., has retired and resigned from the Board. He will continue to provide consulting services to the company. "We are delighted to welcome Kristen and Nancy to our Board of Directors," said Tom King, Executive Chairman of Achieve's Board of Directors. "Their wea

      1/10/25 8:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

      SEATTLE and VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced that Mark Oki has joined the company as its Chief Financial Officer, effective December 5, 2024. Mr. Oki will oversee the company's financial strategy and operations, including accounting, investor relations, information technology, legal and other key administrative functions, ensuring effective planning and execution to support organizational objectives. "Mark's extensive financial, strategic, and opera

      12/9/24 8:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

      Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa

      5/28/24 9:30:00 AM ET
      $ACHV
      $ALGS
      $DCTH
      $PNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medical/Dental Instruments

    $ACHV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Achieve Life Sciences with a new price target

      Rodman & Renshaw initiated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $12.00

      11/14/24 7:20:56 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Raymond James initiated coverage on Achieve Life Sciences with a new price target

      Raymond James initiated coverage of Achieve Life Sciences with a rating of Strong Buy and set a new price target of $20.00

      9/27/24 7:26:18 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Maxim Group reiterated coverage on Achieve Life Sciences with a new price target

      Maxim Group reiterated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $20.00 from $8.00 previously

      5/10/23 11:34:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    SEC Filings

    See more

    $ACHV
    Financials

    Live finance-specific insights

    See more

    $ACHV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ACHV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 10-Q filed by Achieve Life Sciences Inc.

      10-Q - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)

      5/13/25 7:38:20 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)

      5/13/25 7:34:08 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Achieve Life Sciences Inc.

      SCHEDULE 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

      5/9/25 1:01:44 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

      Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for first quarter 2025 and confirmed that it plans to submit the upcoming New Drug Application (NDA) for cytisinicline to the U.S. Food and Drug Administration (FDA) in June 2025. "The Achieve team is fully

      5/13/25 7:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

      SEATTLE and VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that it will report its first quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday May 13, 2025, at 8:30 AM EDT. To access the webcast, please use the following link: 1Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and r

      5/6/25 8:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

      Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for the fourth quarter and year-end 2024 and reiterated its plans to submit its new drug application (NDA) for cytisinicline at the end of the second quarter of 2025. Recent Hig

      3/11/25 7:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Financial Officer Oki Mark K bought $28,887 worth of shares (10,000 units at $2.89) (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/19/25 4:38:43 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chieve Executive Officer Stewart Richard Alistair bought $28,598 worth of shares (10,000 units at $2.86), increasing direct ownership by 20% to 60,876 units (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/19/25 4:32:22 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Principal Accounting Officer Wan Jerry

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      1/30/25 4:54:30 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Achieve Life Sciences Inc.

      SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

      11/12/24 12:14:09 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Achieve Life Sciences Inc.

      SC 13G - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

      11/4/24 10:59:37 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Achieve Life Sciences Inc. (Amendment)

      SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

      5/20/24 5:01:27 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care